Edition:
United States

Medtronic PLC (MDT.N)

MDT.N on New York Stock Exchange

79.62USD
22 Feb 2017
Change (% chg)

$-0.94 (-1.17%)
Prev Close
$80.56
Open
$80.35
Day's High
$80.42
Day's Low
$79.24
Volume
1,469,036
Avg. Vol
1,718,348
52-wk High
$89.27
52-wk Low
$69.35

Latest Key Developments (Source: Significant Developments)

Medtronic's Endurant(TM) II/IIs stent graft system receives CE mark for use with chEVAR parallel graft technique
Tuesday, 6 Dec 2016 06:00am EST 

Medtronic Plc :Medtronic's Endurant(TM) II/IIs stent graft system receives CE mark for use with chEVAR parallel graft technique.  Full Article

Medtronic announces reimbursement approval and launch of CoreValve Evolut R system in Japan
Thursday, 1 Dec 2016 09:30am EST 

Medtronic Plc - : Medtronic announces reimbursement approval and launch of CoreValve(TM) Evolut(TM) R system in Japan .Received reimbursement approval from Japanese MHLW for recapturable, self-expanding transcatheter CoreValve Evolut R system.  Full Article

Medtronic CEO says disappointed by Q2, but headwinds are largely temporary: Conf Call
Tuesday, 22 Nov 2016 08:30am EST 

Medtronic Plc : Medtronic CEO says he expects pressures in CRHF (part of Medtronic's heart division) to continue through the fiscal year . Medtronic CEO says he expects diabetes unit to return to double digit growth once their "artificial pancreas" device is fully on the market next fiscal year . Medtronic CEO says spine division growth was 1 percent - strongest growth in seven quarters - and gained global spine share . Medtronic CEO: Lower-than-expected emerging market revenue, hurt by middle east where revenue fell as government's deal with higher deficit due to falling oil prices . Medtronic CEO says disappointed by Q2, but headwinds are largely temporary Further company coverage: [MDT.N] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Medtronic Q2 non-GAAP earnings per share $1.12
Tuesday, 22 Nov 2016 06:50am EST 

Medtronic PLC : Company reported Q2 worldwide revenue of $7.345 billion, an increase of 4 percent, or 3 percent on a constant currency basis . Medtronic PLC - now expects fiscal year 2017 revenue growth to be within mid-single digit range on a constant currency . "some of challenges that affected revenue in Q2 could persist in near term" . Qtrly Restorative Therapies Group worldwide revenue of $1.826 billion up 4 percent, or 3 percent on a constant currency basis . Qtrly spine revenue of $663 million increased 2 percent, or 1 percent on a constant currency basis . Medtronic PLC - expects free cash flow for fiscal year 2017 to be in range of $5 to $6 billion . Medtronic -starting this quarter, modifying free cash flow outlook methodology to more closely align free cash flow projection with results each quarter . Qtrly Cardiac and Vascular Group Worldwide revenue of $2.584 billion up 4 percent, or 3 percent on a constant currency basis . Medtronic PLC - expects non-GAAP diluted EPS growth for second half of fiscal year 2017 to be in 8 percent to 10 percent range on a constant currency basis . FY 2017 earnings per share view $4.66 -- Thomson Reuters I/B/E/S . FY 2017 revenue view $30.10 billion -- Thomson Reuters I/B/E/S . "Q2 revenue was disappointing and did not meet our expectations" . Medtronic reports second quarter financial results . Q2 GAAP earnings per share $0.80 . Sees FY 2017 non-GAAP earnings per share $4.55 to $4.60.  Full Article

Medtronic licensed by Health Canada to conduct full-body MRI
Tuesday, 8 Nov 2016 09:00am EST 

Medtronic Plc :Medtronic Canada-Health Canada licence and first canadian implants of new specify surescan mri surgical leads.  Full Article

FDA says Heartware Inc recalling HVAD pumps due to design problem with driveline connector
Tuesday, 25 Oct 2016 08:59am EDT 

U.S. Food and Drug Administration: Heartware Inc recalling the HVAD pumps due to a design problem with the driveline connector .contamination of Heartware's driveline may result in fluid or other material entering pump, causing electrical issues or pump stops.  Full Article

U.S. FDA approves first automated insulin delivery device for type 1 diabetes
Wednesday, 28 Sep 2016 01:34pm EDT 

U.S. FDA: FDA approves first automated insulin delivery device for type 1 diabetes . Approved Medtronic’s MiniMed 670G hybrid closed looped system . Medtronic is currently performing clinical studies to evaluate the safety and effectiveness of device in diabetic children 7-13 years old .As part of approval, FDA is requiring a post-market study to better understand how device performs in "real-world settings".  Full Article

Medtronic receives FDA clearance of TrailBlazer angled peripheral support catheter
Wednesday, 28 Sep 2016 09:00am EDT 

Medtronic Plc : Medtronic receives FDA clearance of TrailBlazer angled peripheral support catheter .FDA clearance was received on September 23, 2016.  Full Article

Medtronic Q1 adj EPS of $1.03
Thursday, 25 Aug 2016 06:45am EDT 

Medtronic PLC : Q1 revenue $7.2 billion . Says company reiterates FY 2017 revenue outlook and EPS guidance . Qtrly GAAP diluted EPS of $0.66 . Qtrly non-GAAP diluted EPS of $1.03 . Q1 earnings per share view $1.01, revenue view $7.17 billion -- Thomson Reuters I/B/E/S . Qtrly Restorative Therapies Group worldwide revenue of $1.772 billion decreased 2 percent . Qtrly Spine Division revenue of $645 million decreased 6 percent, or was flat on a cccw basis . Qtrly Cardiac and Vascular group worldwide revenue of $2.518 billion decreased 2 percent . FY 2017 earnings per share view $4.66, revenue view $29.95 billion -- Thomson Reuters I/B/E/S .  Full Article

Medtronic reports a passive stake of 8.6 pct in Mazor Robotics
Monday, 22 Aug 2016 05:13pm EDT 

Mazor Robotics Ltd :Medtronic Plc reports a passive stake of 8.6 pct in Mazor Robotics Ltd as of August 11, 2016 - SEC filing.  Full Article

More From Around the Web

Medtronic's sales, profit beat estimates; shares rise

Medtronic Plc reported quarterly sales and profit above Wall Street estimates, driven by higher demand for its heart, vascular and minimally invasive products.